Tirzepatide

Tirzepatide is a dual-acting peptide agonist that targets both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. These two incretin hormones play , tirzepatide uk  complementary roles in regulating postprandial insulin secretion, appetite signalling, and energy metabolism, and their combined activation through Tirzepatide has been the subject of considerable research interest. Studies have investigated how Tirzepatide influences blood glucose homeostasis by enhancing insulin release in a glucose-dependent manner, thereby reducing the risk of hypoglycaemia compared to some other glucose-lowering agents. Researchers have also examined its effect on appetite suppression and caloric intake, with findings suggesting significant reductions in body weight in study subjects. Beyond glycaemic and weight-related parameters, research has explored Tirzepatide’s potential effects on cardiovascular risk markers, including improvements in triglyceride levels and blood pressure. As a dual incretin mimetic, it represents an important area of investigation for the scientific community studying the intersection of metabolic syndrome, type 2 diabetes, and obesity-related complications.